Australia - English - Department of Health (Therapeutic Goods Administration)

vitex pharmaceuticals pty ltd - acetyl levocarnitine hydrochloride, quantity: 500 mg; levocarnitine tartrate, quantity: 1000 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; carnauba wax; magnesium stearate; stearic acid; colloidal anhydrous silica; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000; lecithin; hyprolose; silicon dioxide; carmellose sodium - maintain/support general health and wellbeing

Australia - English - Department of Health (Therapeutic Goods Administration)

fit-bioceuticals pty ltd - acetyl levocarnitine hydrochloride, quantity: 500 mg - capsule, hard - excipient ingredients: magnesium stearate; microcrystalline cellulose; purified water; gelatin - antioxidant/reduce free radicals formed in the body ; maintain/support energy levels ; maintain/support energy production ; maintain/support physical endurance/capacity/stamina ; maintain/support general health and wellbeing ; maintain/support healthy body fat/muscle composition ; helps maintain/support healthy cholesterol ; maintain/support heart health ; aid/assist/helps post exercise recovery ; helps enhance/improve muscle recovery time ; decrease/reduce mental/cognitive fatigue ; enhance/improve/promote/increase cognitive performance ; maintain/support cognitive function/mental function ; maintain/support memory/mental recall ; maintain/support brain function ; aid/assist/helps synthesis of neurotransmitters ; maintain/support nervous system function ; maintain/support reproductive system health ; maintain/support healthy sexual function ; maintain/support sperm health ; maintain/support sperm motility ; maintain/support sperm production

Australia - English - Department of Health (Therapeutic Goods Administration)

herbs of gold pty ltd - acetyl levocarnitine hydrochloride, quantity: 500 mg - capsule, hard - excipient ingredients: magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; hypromellose; purified water; sorbitol; silicon dioxide - antioxidant/reduce free radicals formed in the body ; helps convert (state food) into energy ; maintain/support energy production ; maintain/support cardiovascular system health ; maintain/support muscle performance/endurance/stamina ; aid/assist/helps post exercise recovery ; aid/assist/helps metabolism of (state vitamin/mineral/nutrient) ; maintain/support cognitive function/mental function ; maintain/support brain function ; maintain/support nerve conduction ; aid/assist/helps synthesis of neurotransmitters ; maintain/support nervous system health ; maintain/support nervous system function ; maintain/support sperm health ; maintain/support sperm motility ; maintain/support sperm production

Australia - English - Department of Health (Therapeutic Goods Administration)

metagenics (aust) pty ltd - acetyl levocarnitine hydrochloride, quantity: 784.3 mg/g - powder, oral - excipient ingredients: colloidal anhydrous silica; calcium hydrogen phosphate dihydrate; maltodextrin - maintain/support energy levels ; maintain/support energy production ; relieve weariness/tiredness/fatigue/feeling of weakness ; aid/assist/helps metabolism of (state vitamin/mineral/nutrient) ; decrease/reduce mental/cognitive fatigue ; maintain/support mental concentration/focus/clarity ; maintain/support cognitive function/mental function ; maintain/support nervous system function

Australia - English - Department of Health (Therapeutic Goods Administration)

phytologic holdings pty limited - acetyl levocarnitine hydrochloride, quantity: 500 mg - capsule, hard - excipient ingredients: purified water; hypromellose; silicon dioxide; magnesium stearate; sorbitol - maintain/support energy levels ; maintain/support energy production ; maintain/support general health and wellbeing ; aid/assist/helps metabolism of (state vitamin/mineral/nutrient) ; aid/assist/helps synthesis of neurotransmitters

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 200 mg in 1 ml - acetylcysteine is the nonproprietary name for the n-acetyl derivative of the naturally occurring amino acid, l-cysteine. chemically, it is n-acetyl-l-cysteine. the compound is a white crystalline powder which melts in the range of 104° to 110°c and has a very slight odor. the structural formula of acetylcysteine is: c5 h9 no3 s                                                                                                      m.w.=163.19 acetylcysteine solution, usp is supplied as a sterile unpreserved solution (not for injection) in vials containing a 10% (100 mg/ml) or 20% (200 mg/ml) solution of acetylcysteine as the sodium salt. the inactive ingredients are edetate disodium, sodium hydroxide and sterile water for injection, usp. the ph of the solution ranges from 6.0 to 7.5. it is administered by inhalation or direct instillation for mucolysis, or orally for acetaminophen overdosage.

United States - English - NLM (National Library of Medicine)

cardinal health 107, llc - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 200 mg in 1 ml - acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) pulmonary complications of cystic fibrosis tracheostomy care pulmonary complications associated with surgery use during anesthesia post-traumatic chest conditions atelectasis due to mucous obstruction diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) acetylcysteine is contraindicated in those patients who are sensitive to it. acetylcysteine, administered orally, is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen. it is essential to initiate treatment as soon as possible after the overdose and, in any case, within 24 hours of ingestion. there are no contraindications to oral administration of acetylcysteine in the treatment of acetaminophen overdose.

United States - English - NLM (National Library of Medicine)

american regent, inc. - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 100 mg in 1 ml - acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) pulmonary complications of cystic fibrosis tracheostomy care pulmonary complications associated with surgery use during anesthesia post-traumatic chest conditions atelectasis due to mucous obstruction diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) acetylcysteine is contraindicated in those patients who are sensitive to it. acetylcysteine, administered orally, is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen. it is essential to initiate treatment as soon as po

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 100 mg in 1 ml - acetylcysteine solution, usp is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) pulmonary complications of cystic fibrosis tracheostomy care pulmonary complications associated with surgery use during anesthesia post-traumatic chest conditions atelectasis due to mucous obstruction diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) acetylcysteine is contraindicated in those patients who are sensitive to it. acetylcysteine solution, usp administered orally, is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen. it is essential to initiate trea

United States - English - NLM (National Library of Medicine)

hospira, inc. - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 100 mg in 1 ml - acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: chronic bronchopulmonary disease     (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) acute bronchopulmonary disease     (pneumonia, bronchitis, tracheobronchitis) pulmonary complications of cystic fibrosis tracheostomy care pulmonary complications associated with surgery use during anesthesia post-traumatic chest conditions atelectasis due to mucous obstruction diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) acetylcysteine is contraindicated in those patients who are sensitive to it. acetylcysteine, administered orally, is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen. it is essential to initiate treatment as soon as